Trade Otonomy, Inc. - OTIC CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Trading Conditions
| Long position overnight fee | -0.0225% |
| Short position overnight fee | -0.0219% |
| Overnight fee time | 21:00 (UTC) |
| Min traded quantity | 1 |
| Currency | USD |
| Margin | 20% |
| Stock exchange | United States of America |
| Commission on trade | 0% |
*Information provided by Capital.com
Key Stats
| Prev. Close* | 0.39 |
| Open* | 0.38 |
| Day's Range* | 0.38 - 0.38 |
| 1-Year Change* | -5% |
| Volume | N/A |
| Average Vol. (3m) | 30.9977 |
| 52 wk Range | N/A |
| Market Cap | 21.0864 |
| P/E Ratio | N/A |
| Shares Outstanding | 56990400 |
| Revenue | N/A |
| EPS | -0.78209 |
| Dividend (Yield %) | N/A |
| Beta | 1.19603 |
| Next Earnings Date | Nov 8, 2022 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Aug 9, 2022 | 0.38 | 0.00 | 0.00% | 0.38 | 0.38 | 0.38 |
| Aug 3, 2022 | 0.39 | 0.00 | 0.00% | 0.39 | 0.44 | 0.39 |
| Aug 1, 2022 | 0.39 | -0.01 | -2.50% | 0.40 | 0.40 | 0.39 |
| Jul 29, 2022 | 1.40 | -0.11 | -7.28% | 1.51 | 1.52 | 1.32 |
| Jul 28, 2022 | 1.49 | -0.19 | -11.31% | 1.68 | 1.70 | 1.43 |
| Jul 27, 2022 | 1.74 | -0.04 | -2.25% | 1.78 | 1.83 | 1.66 |
| Jul 26, 2022 | 1.81 | -0.12 | -6.22% | 1.93 | 1.93 | 1.61 |
| Jul 25, 2022 | 1.92 | -0.03 | -1.54% | 1.95 | 2.01 | 1.88 |
| Jul 22, 2022 | 1.97 | 0.09 | 4.79% | 1.88 | 2.02 | 1.81 |
| Jul 21, 2022 | 1.91 | -0.03 | -1.55% | 1.94 | 1.98 | 1.86 |
| Jul 20, 2022 | 2.18 | 0.06 | 2.83% | 2.12 | 2.26 | 2.12 |
| Jul 19, 2022 | 2.20 | 0.08 | 3.77% | 2.12 | 2.29 | 2.10 |
| Jul 18, 2022 | 2.12 | 0.04 | 1.92% | 2.08 | 2.16 | 2.05 |
| Jul 15, 2022 | 2.11 | 0.09 | 4.46% | 2.02 | 2.11 | 1.93 |
| Jul 14, 2022 | 1.96 | -0.19 | -8.84% | 2.15 | 2.22 | 1.91 |
| Jul 13, 2022 | 2.19 | 0.00 | 0.00% | 2.19 | 2.25 | 2.18 |
| Jul 12, 2022 | 2.20 | 0.10 | 4.76% | 2.10 | 2.20 | 2.10 |
| Jul 11, 2022 | 2.18 | 0.09 | 4.31% | 2.09 | 2.21 | 2.09 |
| Jul 8, 2022 | 2.17 | 0.08 | 3.83% | 2.09 | 2.21 | 2.09 |
| Jul 7, 2022 | 2.15 | 0.08 | 3.86% | 2.07 | 2.20 | 2.06 |
Otonomy, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Tuesday, November 8, 2022 | ||
| 10:59 | | Q3 2022 Otonomy Inc Earnings Release |
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Total revenue | 0.683 | 1.236 | 0.745 | 0.6 | 0.273 | 0.125 |
| Revenue | 0.683 | 1.236 | 0.745 | 0.6 | 0.273 | 0.125 |
| Cost of Revenue, Total | 1.664 | 3.098 | 0.934 | 0.912 | 0.888 | 0.37 |
| Gross Profit | -0.981 | -1.862 | -0.189 | -0.312 | -0.615 | -0.245 |
| Total Operating Expense | 112.164 | 92.637 | 52.798 | 45.407 | 43.76 | 49.75 |
| Selling/General/Admin. Expenses, Total | 49.777 | 46.838 | 20.008 | 11.69 | 14.575 | 14.707 |
| Research & Development | 60.723 | 42.701 | 31.856 | 32.805 | 27.997 | 34.673 |
| Operating Income | -111.481 | -91.401 | -52.053 | -44.807 | -43.487 | -49.625 |
| Interest Income (Expense), Net Non-Operating | 0.899 | 1.271 | 1.685 | 0.132 | -1.244 | -1.556 |
| Other, Net | -0.001 | 0 | 0 | |||
| Net Income Before Taxes | -110.583 | -90.13 | -50.368 | -44.675 | -44.731 | -51.181 |
| Net Income After Taxes | -110.583 | -90.13 | -50.368 | -44.675 | -44.731 | -51.181 |
| Net Income Before Extra. Items | -110.583 | -90.13 | -50.368 | -44.675 | -44.731 | -51.181 |
| Net Income | -110.583 | -90.13 | -50.368 | -44.675 | -44.731 | -51.181 |
| Total Adjustments to Net Income | 0 | |||||
| Income Available to Common Excl. Extra. Items | -110.583 | -90.13 | -50.368 | -44.675 | -44.731 | -51.181 |
| Income Available to Common Incl. Extra. Items | -110.583 | -90.13 | -50.368 | -44.675 | -44.731 | -51.181 |
| Diluted Net Income | -110.583 | -90.13 | -50.368 | -44.675 | -44.731 | -51.181 |
| Diluted Weighted Average Shares | 29.9628 | 30.3042 | 30.6102 | 30.7268 | 40.8458 | 63.4413 |
| Diluted EPS Excluding Extraordinary Items | -3.69068 | -2.97418 | -1.64546 | -1.45394 | -1.09512 | -0.80675 |
| Diluted Normalized EPS | -3.69068 | -2.97418 | -1.64546 | -1.45394 | -1.08777 | -0.79571 |
| Total Extraordinary Items | 0 | |||||
| Unusual Expense (Income) | 0.3 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0.09 | 0.035 | 0 | 0 | 0 |
| Revenue | 0.09 | 0.035 | 0 | 0 | 0 |
| Cost of Revenue, Total | 0.23 | 0.14 | 0 | 0 | 0 |
| Gross Profit | -0.14 | -0.105 | 0 | 0 | 0 |
| Total Operating Expense | 11.933 | 12.166 | 12.479 | 13.172 | 13.154 |
| Selling/General/Admin. Expenses, Total | 4.043 | 3.669 | 3.501 | 3.494 | 3.748 |
| Research & Development | 7.66 | 8.357 | 8.978 | 9.678 | 9.406 |
| Operating Income | -11.843 | -12.131 | -12.479 | -13.172 | -13.154 |
| Interest Income (Expense), Net Non-Operating | -0.367 | -0.381 | -0.401 | -0.407 | -0.398 |
| Net Income Before Taxes | -12.21 | -12.512 | -12.88 | -13.579 | -13.552 |
| Net Income After Taxes | -12.21 | -12.512 | -12.88 | -13.579 | -13.552 |
| Net Income Before Extra. Items | -12.21 | -12.512 | -12.88 | -13.579 | -13.552 |
| Net Income | -12.21 | -12.512 | -12.88 | -13.579 | -13.552 |
| Income Available to Common Excl. Extra. Items | -12.21 | -12.512 | -12.88 | -13.579 | -13.552 |
| Income Available to Common Incl. Extra. Items | -12.21 | -12.512 | -12.88 | -13.579 | -13.552 |
| Diluted Net Income | -12.21 | -12.512 | -12.88 | -13.579 | -13.552 |
| Diluted Weighted Average Shares | 52.3191 | 65.6278 | 67.7924 | 67.856 | 67.8457 |
| Diluted EPS Excluding Extraordinary Items | -0.23338 | -0.19065 | -0.18999 | -0.20012 | -0.19975 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.23338 | -0.19065 | -0.18999 | -0.20012 | -0.19975 |
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 202.22 | 122.445 | 100.069 | 63.15 | 88.715 | 80.468 |
| Cash and Short Term Investments | 196.378 | 120.004 | 97.284 | 60.67 | 86.343 | 77.412 |
| Cash & Equivalents | 24.156 | 18.456 | 33.633 | 25.194 | 30.767 | 77.412 |
| Short Term Investments | 172.222 | 101.548 | 63.651 | 35.476 | 55.576 | 0 |
| Total Receivables, Net | 0.091 | 0.107 | 0.108 | 0.048 | ||
| Accounts Receivable - Trade, Net | 0.091 | 0.107 | 0.108 | 0.048 | ||
| Total Inventory | 1.435 | 0.006 | 0.227 | |||
| Prepaid Expenses | 2.161 | 0.729 | 0.258 | 0.209 | 3.056 | |
| Other Current Assets, Total | 2.155 | 1.599 | 2.419 | 2.223 | 2.145 | |
| Total Assets | 208.596 | 128.364 | 104.992 | 83.018 | 106.265 | 95.637 |
| Property/Plant/Equipment, Total - Net | 4.977 | 4.679 | 3.996 | 19.167 | 16.848 | 14.467 |
| Property/Plant/Equipment, Total - Gross | 6.817 | 7.373 | 7.843 | 24.014 | 22.727 | 20.847 |
| Accumulated Depreciation, Total | -1.84 | -2.694 | -3.847 | -4.847 | -5.879 | -6.38 |
| Other Long Term Assets, Total | 1.399 | 1.24 | 0.927 | 0.701 | 0.702 | 0.702 |
| Total Current Liabilities | 15.233 | 8.191 | 7.49 | 12.498 | 10.994 | 12.333 |
| Accounts Payable | 1.292 | 0.961 | 1.029 | 1.061 | 0.749 | 0.99 |
| Accrued Expenses | 13.903 | 7.188 | 6.423 | 11.364 | 10.227 | 11.252 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.038 | 0.042 | 0.038 | 0 | ||
| Total Liabilities | 15.859 | 11.085 | 25.255 | 42.785 | 39.999 | 40.73 |
| Total Long Term Debt | 0 | 0 | 14.764 | 14.981 | 15.158 | 16.205 |
| Other Liabilities, Total | 0.626 | 2.894 | 3.001 | 15.306 | 13.847 | 12.192 |
| Total Equity | 192.737 | 117.279 | 79.737 | 40.233 | 66.266 | 54.907 |
| Common Stock | 0.03 | 0.031 | 0.031 | 0.031 | 0.048 | 0.057 |
| Additional Paid-In Capital | 467.468 | 482.198 | 494.947 | 500.084 | 570.841 | 610.655 |
| Retained Earnings (Accumulated Deficit) | -274.72 | -364.85 | -415.218 | -459.893 | -504.624 | -555.805 |
| Other Equity, Total | -0.041 | -0.1 | -0.023 | 0.011 | 0.001 | 0 |
| Total Liabilities & Shareholders’ Equity | 208.596 | 128.364 | 104.992 | 83.018 | 106.265 | 95.637 |
| Total Common Shares Outstanding | 30.2553 | 30.5587 | 30.6854 | 30.8142 | 48.319 | 56.7325 |
| Redeemable Preferred Stock | 0 | 0 | 0 | |||
| Long Term Debt | 14.764 | 14.967 | 15.158 | 15.997 | ||
| Current Port. of LT Debt/Capital Leases | 0.073 | 0.018 | 0.091 | |||
| Capital Lease Obligations | 0.014 | 0 | 0.208 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 76.877 | 99.352 | 89.287 | 80.468 | 66.378 |
| Cash and Short Term Investments | 73.829 | 97.878 | 87.096 | 77.412 | 62.874 |
| Cash & Equivalents | 51.016 | 85.096 | 81.843 | 77.412 | 62.874 |
| Short Term Investments | 22.813 | 12.782 | 5.253 | 0 | |
| Total Inventory | 0.455 | ||||
| Other Current Assets, Total | 2.593 | ||||
| Total Assets | 93.406 | 115.419 | 104.878 | 95.637 | 81.232 |
| Property/Plant/Equipment, Total - Net | 15.605 | 15.153 | 14.677 | 14.467 | 14.152 |
| Property/Plant/Equipment, Total - Gross | 21.705 | 21.172 | 20.908 | 20.847 | 20.72 |
| Accumulated Depreciation, Total | -6.1 | -6.019 | -6.231 | -6.38 | -6.568 |
| Other Long Term Assets, Total | 0.924 | 0.914 | 0.914 | 0.702 | 0.702 |
| Total Current Liabilities | 10.696 | 8.83 | 9.742 | 12.333 | 10.038 |
| Accounts Payable | 0.473 | 1.259 | 0.467 | 0.99 | 1.347 |
| Accrued Expenses | 8.266 | 7.571 | 9.275 | 11.252 | 8.6 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 1.957 | 0.091 | 0.091 | ||
| Total Liabilities | 37.382 | 37.766 | 38.34 | 40.73 | 37.983 |
| Total Long Term Debt | 13.246 | 15.913 | 15.955 | 16.205 | 16.232 |
| Long Term Debt | 13.246 | 15.913 | 15.955 | 15.997 | 16.04 |
| Other Liabilities, Total | 13.44 | 13.023 | 12.643 | 12.192 | 11.713 |
| Total Equity | 56.024 | 77.653 | 66.538 | 54.907 | 43.249 |
| Redeemable Preferred Stock | 0 | 0 | |||
| Common Stock | 0.048 | 0.057 | 0.057 | 0.057 | 0.057 |
| Additional Paid-In Capital | 572.805 | 606.941 | 608.707 | 610.655 | 612.549 |
| Retained Earnings (Accumulated Deficit) | -516.834 | -529.346 | -542.226 | -555.805 | -569.357 |
| Other Equity, Total | 0.005 | 0.001 | 0 | 0 | |
| Total Liabilities & Shareholders’ Equity | 93.406 | 115.419 | 104.878 | 95.637 | 81.232 |
| Total Common Shares Outstanding | 48.3192 | 56.6813 | 56.6813 | 56.7325 | 56.9216 |
| Prepaid Expenses | 1.474 | 2.191 | 3.056 | 3.504 | |
| Capital Lease Obligations | 0.208 | 0.192 |
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Net income/Starting Line | -110.583 | -90.13 | -50.368 | -44.675 | -44.731 | -51.181 |
| Cash From Operating Activities | -94.305 | -75.307 | -38.434 | -36.925 | -38.874 | -42.418 |
| Cash From Operating Activities | 0.708 | 1.289 | 1.186 | 1.149 | 1.062 | 0.856 |
| Non-Cash Items | 14.655 | 18.237 | 12.011 | 4.292 | 6.273 | 8.381 |
| Changes in Working Capital | 0.915 | -4.703 | -1.263 | 2.309 | -1.478 | -0.474 |
| Cash From Investing Activities | -149.417 | 68.998 | 37.984 | 28.296 | -20.215 | 55.963 |
| Capital Expenditures | -2.546 | -1.259 | -0.496 | -0.7 | -0.134 | -0.295 |
| Other Investing Cash Flow Items, Total | -146.871 | 70.257 | 38.48 | 28.996 | -20.081 | 56.258 |
| Cash From Financing Activities | 109.216 | 1.07 | 15.165 | 0.195 | 64.663 | 33.1 |
| Issuance (Retirement) of Stock, Net | 109.216 | 1.07 | 0.335 | 0.247 | 64.663 | 32.426 |
| Issuance (Retirement) of Debt, Net | 0 | 14.83 | 0 | 0 | 0.674 | |
| Net Change in Cash | -134.506 | -5.239 | 14.715 | -8.434 | 5.574 | 46.645 |
| Cash Interest Paid | 1.394 | 1.373 | 1.422 | |||
| Financing Cash Flow Items | -0.052 | 0 | 0 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -12.21 | -24.722 | -37.602 | -51.181 | -13.552 |
| Cash From Operating Activities | -12.367 | -21.95 | -32.65 | -42.418 | -14.344 |
| Cash From Operating Activities | 0.221 | 0.436 | 0.648 | 0.856 | 0.195 |
| Non-Cash Items | 2.757 | 4.638 | 6.474 | 8.381 | 1.937 |
| Cash Interest Paid | 0.338 | 0.686 | 1.054 | 1.422 | 0.36 |
| Changes in Working Capital | -3.135 | -2.302 | -2.17 | -0.474 | -2.924 |
| Cash From Investing Activities | 32.615 | 43.27 | 50.717 | 55.963 | -0.194 |
| Capital Expenditures | -0.13 | -0.243 | -0.296 | -0.295 | -0.194 |
| Other Investing Cash Flow Items, Total | 32.745 | 43.513 | 51.013 | 56.258 | 0 |
| Cash From Financing Activities | 0.001 | 33.009 | 33.009 | 33.1 | 0 |
| Issuance (Retirement) of Stock, Net | 0.001 | 32.335 | 32.335 | 32.426 | 0 |
| Net Change in Cash | 20.249 | 54.329 | 51.076 | 46.645 | -14.538 |
| Issuance (Retirement) of Debt, Net | 0.674 | 0.674 | 0.674 | ||
| Financing Cash Flow Items | 0 |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com Group 427000+
Traders
71000+
Active clients monthly
$46000000+
Monthly investing volume
$17000000+
Try now Withdrawn each month
Otonomy, Inc. Company profile
About Otonomy Inc
Otonomy, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutics for neurotology. The Company pipeline includes OTIPRIO, OTIVIDEX, OTO-313, and OTO-413. OTIPRIO is a single-dose, physician-administered antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery for the treatment of patients with acute otitis externa (AOE). OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Menieres disease. OTO-313 is a sustained-exposure formulation of gacyclidine, a potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist, in in Phase II for tinnitus. OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) in Phase IIa development for the repair of cochlear synaptopathy, an underlying pathology in age-related and noise-induced hearing loss. OTO-825, a gene therapy for congenital hearing loss.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Otonomy Inc revenues decreased 54% to $125K. Net loss increased 14% to $51.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 23% to $31.3M (expense), Stock-based Com increase of 37% to $3.4M (expense).
| Industry: | Bio Therapeutic Drugs |
5626 Oberlin Drive, Suite 100
SAN DIEGO
CALIFORNIA 92121
US
Income statement
News
Mexico's Pemex requests $6.5 bln more funding for 'Dos Bocas' refinery -documents, source
Adds detail
19:26, 12 August 2022
3M demerger: MMM spin off Food Safety Business SpinCo merger with Neogen timing and details in full
3M (MMM) has revealed further details about its $5.3bn scheme to spin off its food-safety business. Added to the demerger of its health care products division, 3M is taking steps to lift its stock price.
19:21, 12 August 2022
US and Europe gas prices: What's the impact of heatwaves and hurricanes?
Demand for cooling is soaring in Europe as temperatures climb, adding to market pressure
18:51, 12 August 2022
Small cap index: A ‘small window’ for traders before Wyoming symposium
SWAV, SAIL, SWN, and AR lead Russell 2000 and small company stocks
17:42, 12 August 2022
The Palantir revenue outlook has an upside: here’s why
The Palantir revenue outlook slid this week, but key comments by executives of the enigmatic data software firm point to quiet confidence in a comeback
15:59, 12 August 2022People Also Watch
US Tech 100 (Nasdaq)
13,566.40 Price
| Long position overnight fee | -0.0116% |
| Short position overnight fee | 0.0025% |
| Overnight fee time | 21:00 (UTC) |
| Spread | 1.5 |
Trade now
Still looking for a broker you can trust?
Join the 427.000+ traders worldwide that chose to trade with Capital.com
